# US 2023/0399615 A1 · Icos critically regulates the expansion and function of inflammatory human th17 cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0399615 A1
- Document ID: US20230399615A1
- Status: Published application
- Kind: A1
- Application number: 18/117,255
- Filed: 2023-03-03
- Published: 2023-12-14
- Earliest claimed: 2010-02-04
- Assignees: The Trustees of the University of Pennsylvania
- Applicants: The Trustees of the University of Pennsylvania
- Inventors: James L. Riley; Chrystal Paulos; Carl H. June; Bruce L. Levine
- Web page: https://patentgrep.com/patent/US20230399615A1

## CPC

- C12N 5/0636: {T lymphocytes}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/4255: {Mesothelin [MSLN]}
- A61P 11/06: Antiasthmatics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- C12N 2501/2301: Interleukin-1 (IL-1)
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2306: Interleukin-6 (IL-6)
- C12N 2501/2321: Interleukin-21 (IL-21)
- C12N 2501/2323: Interleukin-23 (IL-23)
- C12N 2501/51: B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2501/599: with CD designations not provided for elsewhere
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.

## Claims

### Claim 1

A composition comprising a first agent that is capable of providing a primary activation signal to a T cell and a second agent that is capable of activating ICOS on said T cell.

### Claim at position 2

2-6. (canceled)

### Claim 7 (depends on 1)

The composition of claim 1, wherein said first agent binds CD3 or a component of the TCR/CD3 complex.

### Claim 8 (depends on 1)

The composition of claim 1, wherein said second agent is anti-ICOS antibody or ICOS-L.

### Claim at position 5

9-13. (canceled)

### Claim 14

A method for activating or stimulating a population of T cells, said method comprising: 1) providing a population of cells wherein at least a portion thereof comprises T cells; 2) contacting said population of cells with a composition comprising a first agent that is capable of providing a primary activation signal to said T cells and a second agent that is capable of activating ICOS on said T cells.

### Claim 15 (depends on 14)

The method of claim 14, wherein said contacting said population of cells with a composition comprising a first agent that is capable of providing a primary activation signal to said T cells and a second agent that is capable of activating ICOS on said T cells is in the presence of a Th-17 polarizing agent.

### Claim 16 (depends on 15)

The method of claim 15, wherein said Th-17 polarizing agent is selected from the group consisting of IL-1β, IL-6, neutralizing anti-IFNγ, anti-IL-4, and any combination thereof.

### Claim 17 (depends on 14)

The method of claim 14, wherein said composition comprises a solid phase surface.

### Claim 18 (depends on 14)

The method of claim 14, wherein said composition comprises a human cell line.

### Claim 19 (depends on 18)

The method of claim 18, wherein said human cell line is selected from the group consisting of K562, U937, 721.221, T2, and C1R cells.

### Claim 20 (depends on 18)

The method of claim 18, wherein said cell is genetically modified to express a human Fc7 receptor.

### Claim 21 (depends on 20)

The method of claim 20, wherein said Fc7 receptor is selected from the group consisting of CD32, CD64, and any combination thereof.

### Claim 22 (depends on 14)

The method of claim 14, wherein said first agent binds CD3 or a component of the TCR/CD3 complex.

### Claim 23 (depends on 14)

The method of claim 14, wherein said second agent is anti-ICOS antibody or ICOS-L.

### Claim at position 16

24-32. (canceled)

### Claim 33

A method of immunotherapy comprising administering an ICOS stimulated T cell to a patient in need thereof.

### Claim 34 (depends on 33)

The method of claim 33, wherein said ICOS stimulated T cell has been contacted with a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of a Th-17 polarizing agent.

### Claim 35 (depends on 34)

The method of claim 34, wherein said Th-17 polarizing agent is selected from the group consisting of IL-1β, IL-6, neutralizing anti-IFNγ, anti-IL-4, and any combination thereof.

### Claim 36 (depends on 34)

The method of claim 34, wherein said first agent binds CD3 or a component of the TCR/CD3 complex.

### Claim 37 (depends on 34)

The method of claim 34, wherein said second agent is anti-ICOS antibody or ICOS-L.

### Claim 38 (depends on 34)

The method of claim 34, wherein said Th17 has been contacted with an antigen.

### Claim 39

(canceled)

### Claim 40 (depends on 1)

A method of regulating a Th17 cell in a mammal, said method comprising administering to said mammal an effective amount of the composition of claim 1.
